Oncoimmunity granted NOK 300,000 from Innovation Norway

OncoImmunity provides innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers.


Oncoimmunity is one of Radium Hospital Research Foundation´s portfolio companies. The company is co-localised with the Foundation in the incubator in Oslo Cancer Cluster Innovation Park.


One of the major challenges to overcome is the accurate identification of immunogenic peptides in the tumor, and their precise constellation on a personalized vaccine. In this project OncoImmunity and partners were granted NOK 300.000,- to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.

In this project OncoImmunity and partners were granted NOK 300.000,- to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.